1 Result: Renalytix
Breaking: Renalytix's KidneyIntelX.dkd FDA-Approved, VSE Secures Up to $565M Contract
June 29th, 2023
Shares of Renalytix plc (Nasdaq: RNLX) surged over 25% in after-hours trading following the company's announcement of receiving De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its KidneyIntelX.dkd prognostic test.. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Earnings Due: Wall Street Eyes Goldman Sachs, Fastenal, FB Financial
April 12th, 2026Treasury Launches Cybersecurity Information Sharing Initiative for the Digital Asset Industry
April 09th, 2026How Eligibility Protection Is Creating New Opportunities for Football Athletes After High School
April 08th, 2026Cryptocurrency and AI Scams Bilk Americans of Billions
April 06th, 2026
Member Login